High-Throughput TB Vaccine Antigen Discovery

Information

  • Research Project
  • 10242744
  • ApplicationId
    10242744
  • Core Project Number
    K08AI135098
  • Full Project Number
    5K08AI135098-05
  • Serial Number
    135098
  • FOA Number
    PA-16-191
  • Sub Project Id
  • Project Start Date
    6/1/2019 - 5 years ago
  • Project End Date
    8/31/2023 - a year ago
  • Program Officer Name
    MENDEZ, SUSANA
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    05
  • Suffix
  • Award Notice Date
    8/11/2021 - 3 years ago
Organizations

High-Throughput TB Vaccine Antigen Discovery

Project Summary/Abstract: Approximately one third of the world's population is infected with latent tuberculosis (LTBI). While BCG vaccination protects some children against pediatric tuberculous meningitis, it does not prevent the most prevalent form of disease, pulmonary TB disease in adults. To date, every new tuberculosis (TB) vaccine candidate has failed in large-scale clinical trials and no known immune correlates of vaccine protection for TB have been validated. Failure of new TB vaccines such as MVA-85A, despite generating high-magnitude Th1 immune responses against the immunodominant antigen, Ag85A, is likely related to the exclusive use of immunodominant antigens in these vaccines, despite poor correlation of immunodominant responses with vaccine efficacy. These facts highlight a critical need for discovery of novel subdominant TB antigens for use in TB vaccines that can enhance functional immunity and bacterial killing. Here we propose a novel TB antigen discovery platform that enables systematic and unbiased probing of a TB genome-wide DNA vaccine library with the overall objective to identify new TB antigens. Our specific aims are to generate immune responses to pooled subdominant antigens in mice and to identify novel subdominant immunogens with capacity to induce protective immunity. We aim to do this by in vivo interrogation of the TB proteome using the mouse challenge model. Our long-term goal is to inform TB vaccine design and to uncover novel immune correlates of vaccine protection for TB. Achieving these aims has the capacity to transform the TB vaccine field and contribute to the development of an efficacious TB vaccine. The Barouch laboratory at Beth Israel Deaconess Medical Center leads in vaccine design and discovery for diseases such as HIV and Zika virus infection. I aim to synergize my expertise in TB bacteriology and animal models with enhanced training in immunology and vaccinology at the Center for Virology and Vaccine Research to gain the skills necessary to position myself to become a leader in TB vaccine discovery as a principle investigator and head of my own research group.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    K08
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    146751
  • Indirect Cost Amount
    11740
  • Total Cost
    158491
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
    SCHOOLS OF VETERINARY MEDICINE
  • Funding ICs
    NIAID:158491\
  • Funding Mechanism
    OTHER RESEARCH-RELATED
  • Study Section
    MID
  • Study Section Name
    Microbiology and Infectious Diseases B Research Study Section
  • Organization Name
    TUFTS UNIVERSITY BOSTON
  • Organization Department
    VETERINARY SCIENCES
  • Organization DUNS
    039318308
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021111901
  • Organization District
    UNITED STATES